http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
급성전골수구성백혈병에서 PML/RARα 유전자 이형의 임상적 의의
이원식 ( Won Sik Lee ),이상민 ( Sang Min Lee ),이규형 ( Kyoo Hyung Lee ),이제환 ( Je Hwan Lee ),최성준 ( Seong Joon Choi ),이정희 ( Jung Hee Lee ),김대영 ( Dae Young Kim ),임성남 ( Sung Nam Lim ),박재후 ( Jae Hoo Park ),민영주 ( Y 대한내과학회 2008 대한내과학회지 Vol.75 No.4
Background/Aims: There are three types of PML-RARα mRNA fusion transcripts associated with acute promyelocytic leukemia (APL): the short (S)-form, the long (L)-form and the variable (V)-form. No study on the Korean population has addressed the clinical significance of the specific types of PML-RARα mRNA fusion transcripts for APL patients who receive the combination therapy of all-trans-retinoic-acid and idarubicin (AIDA regimen). Methods: We performed a retrospective analysis on 94 patients with APL to evaluate differences in the therapeutic outcomes, such as the response rate, an event-free survival (EFS), and overall survival (OS), after remission following the induction of chemotherapy. We also analyzed whether differences in the pretreatment clinical characteristics depend on the PML-RARα isoform. Results: The median age of the patients was 41 years (range 15-85). Among the 94 patients, there were 58 L-form cases (62.1%), 32 S-form cases (34.0%), and 4 V-form cases (4.3%). The CR rate following remission induction treatment was 84.9%. The CR rate was higher in patients with an initial WBC<10.0×109/L, as compared to patients with an initial WBC higher than 10.0×109/L (93.5% vs. 65.4%, p=0.001). The AIDA induction regimen was associated with a better EFS than non-AIDA induction regimens (81.9% vs. 49.6%, p=0.006). The induction group was also a significant prognostic factor for EFS in the multivariate analysis (p=0.020). There were no differences in OS and EFS in patients with either isoform L or isoform S in the AIDA induction group. Conclusions: This retrospective study demonstrated that pretreatment clinical characteristics and treatment outcomes were not significantly different among patients with varying PML-RARα isoform types in the AIDA induction group. (Korean J Med 75:412-419, 2008)
박건욱(Keon Uk Park),이규형(Kyoo Hyung Lee),이제환(Je Hwan Lee),이기현(Kee Hyun Lee),이정신(Jung Shin Lee),김상희(Sang Hee Kim),김우건(Woo Kun Kim),노재윤(Jae Y Roh) 대한내과학회 2001 대한내과학회지 Vol.60 No.1
Leimyosarcoma of the inferior vena cava is a rare disorder and may present with symptoms of obstruction of the normal flow of blood. We report a case of leiomyosarcoma of the inferior vena cava in 55-year-old female patient. The tumor was discovered incidentally by ultrasonography of the abdomen which was performed to evaluate epigastric pain and indigestion. Further radiological studies including CT and inferior vena cavography confirmed the presence of a 5cm sized mass in the inferior vena cava . The microscopic examination of a specimen obtained by a catheter from inferior vena cava mass revealed malignant mesenchymal tumor. The tumor was completely resected with reconstruction of the inferior vena cava and left renal vein. The diagnosis of leiomyosarcoma was made by micoscopic and immunohistochemical findings of the resected tumor.(Korean J Med 60:92-96, 2001)
급성 골수성 백혈병에서 고용량 Cytarabine 을 이용한 공고요법
김도하(Do Ha Kim),이규형(Kyoo Hyung Lee),조재근(Jae Kun Cho),김선희(Seon Hee Kim),이제환(Je Hwan Lee),김성배(Sung Bae Kim),김상위(Sang We Kim),서철원(Chul Won Suh),이정신(Jung Shin Lee),김우건(Woo Kun Kim),김상희(Sang Hee Kim) 대한내과학회 1996 대한내과학회지 Vol.51 No.4
Objectives: This study was designed to evaluate the therapeutic efficacy of postremission therapy utilizing high-dose cytarabine in patients with newly diagnosed acute myelogenous leukemia and to assess the toxicities of the therapy. Acute promyelocytic leukemia (FAB M3) is excluded because it has very unique clinicopathologic characteristics. Methods: Those patients who achieved complete remission had first consolidation therapy with conventional dose cytarabine and daunorubicin but second and third consolidation was done with high-dose cytarabine (cytarabine 1gm/㎡ i.v. over 1 hour every 12 hours daily for 5 days) and daunorubicin. Overall survival and disease free survival were compared with previous conventional dose cytarabine and daunorubicin postremission therapy. Results: 1) Complete remission occurred in 62% (28 of 45 patients) and control group 48% (14 of 29 patients) (p=0.15). 2) The median survival of all 45 patients was not different significantly compared with control group (10 months vs 7 months, p=0.08). 3) The median disease free survival of 21 complete responders receiving at least one course of consolidation was 10 months and there was no significant difference compared with control group 7 months (p=0.47). 4) The toxicity including treatment-related motility, neutropenia duration was similar in both groups. Conclusion: Although our high-dose cytarabine consolidation therapy regimen appeared to have acceptable toxicity, its results did not show the superiority to previous conventional dose cytarabine consolidation regimen.
성인 급성 림프구성 백혈병의 예후 : - 33 예의 환자들을 대상으로 한 분석 -
조유숙(You Sook Cho),이규형(Kyoo Hyung Lee),이제환(Je Hwan Lee),김성배(Sung Bae Kim),김상위(Sang We Kim),서철원(Cheol Won Suh),이정신(Jung Shin Lee),김우건(Woo Kun Kim),김상희(Sang Hee Kim),지현숙(Hyun Sook Chi),박찬정(Chan Jung Park 대한내과학회 1997 대한내과학회지 Vol.52 No.3
Objectives: Rate of complete remission and long-term survival in adult acute lymphoblastic leukemia group has not been as satisfactory as that in childhood ALL. Recently introduction of induction chemotherapy of more intensive combination and various trials of postremission therapy are making improved results better looked forward to. And subtypes of ALL according to the degree of differentiation into T and B cells are identified by using immunologic markers hopefully to work out proper treatment for each subtype. Methods: We analited results of treatment and differences of complete remission rate, remission duration and overall survival as to various immunologic markers and clinicopathologic characteristics in 33adult ALL patients. Results: Eighty five percents of the 27cases that had VPDL chemotherapy achieved complete remission and both overall median survival and mediom duration of remission were 52weeks. No definite prognostic factors were detected influencing complete remission rate, remission duration and overall survival except that patients with serum albumin level higher than 4.0mg/dL showed highter complete remission rate. Although mature B-ALL showed the shortest overall median survival, degree of differenciation of B-cell and other immunologic markers did not influence on complete remission rate, remission duration or overall survival. Conclusion: Further studies are needed to delire the prognostic factors in adult ALL